[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO327588B1 - Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive - Google Patents

Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive

Info

Publication number
NO327588B1
NO327588B1 NO20083854A NO20083854A NO327588B1 NO 327588 B1 NO327588 B1 NO 327588B1 NO 20083854 A NO20083854 A NO 20083854A NO 20083854 A NO20083854 A NO 20083854A NO 327588 B1 NO327588 B1 NO 327588B1
Authority
NO
Norway
Prior art keywords
drospirenone
composition
daily dosage
ethinylestradiol
approx
Prior art date
Application number
NO20083854A
Other languages
Norwegian (no)
Other versions
NO20083854L (en
NO327588B3 (en
Inventor
Wolfgang Heil
Ralph Lipp
Renate Heithecker
Juergen Hilmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO327588(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2000/001213 external-priority patent/WO2001015701A1/en
Publication of NO20083854L publication Critical patent/NO20083854L/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO327588B1 publication Critical patent/NO327588B1/en
Publication of NO327588B3 publication Critical patent/NO327588B3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives farmasøytiske materialer som omfatter som et første aktive 6?, 7?, 15?, 16?-dimetylen-3-okso-17?-pregn-4-en-21,17-karbolakton (drospirenon) i en mengde korresponderende til en daglig dosering, ved administrering av materialet, fra ca. 2 mg til ca. 4 mg, og som et andre aktive middel 17?-etinylestradiol (etinylestradiol) i en mengde korresponderende til daglig dosering av fra ca. 0,01mg til ca. 0,05 mg, sammen med eller flere farmasøytisk akseptable bærere eller eksipienter. I en spesifikk utførelse omfatter materialet et antall separat pakkede og individuelt fjern-bare daglige dose-ringsenheter plassert i en pakningsenhet og tiltenkt for oral administrering på minst 21 påfølgende dager, hvorpå nevnte daglige doseringsenheter omfatter kombinasjonen av drospirenon og etinylestrediol. Materialet kan videre omfatte 7 eller mindre daglige doseringsenheter som inneholder intet aktivt middel, eller som kun inneholder etinylestradiol.Pharmaceutical materials are disclosed which comprise as a first active 6 ?, 7 ?, 15 ?, 16? -Dimethylene-3-oxo-17? -Pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, when administering the material, from ca. 2 mg to approx. 4 mg, and as a second active agent 17β-ethinylestradiol (ethinylestradiol) in an amount corresponding to daily dosage of from ca. 0.01mg to approx. 0.05 mg, together with or more pharmaceutically acceptable carriers or excipients. In one specific embodiment, the material comprises a plurality of separately packaged and individually removable daily dosing units placed in a packing unit and intended for oral administration of at least 21 consecutive days, said daily dosing units comprising the combination of drospirenone and ethinylestrediol. The material may further comprise 7 or less daily dosage units containing no active agent or containing only ethinyl estradiol.

NO20083854A 1999-08-31 2008-09-08 Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive NO327588B3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24095399P 1999-08-31 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Publications (3)

Publication Number Publication Date
NO20083854L NO20083854L (en) 2002-04-26
NO327588B1 true NO327588B1 (en) 2009-08-31
NO327588B3 NO327588B3 (en) 2011-05-16

Family

ID=26153358

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20083854A NO327588B3 (en) 1999-08-31 2008-09-08 Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive
NO20091809A NO20091809L (en) 1999-08-31 2009-05-07 Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive
NO2010004C NO2010004I1 (en) 1999-08-31 2010-02-26 0.02 mg of ethinylostradiol (as betadexclathrate) and 3mg drospirenone

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20091809A NO20091809L (en) 1999-08-31 2009-05-07 Pharmaceutical material of entinylestradiol and drospirenone for use as a contraceptive
NO2010004C NO2010004I1 (en) 1999-08-31 2010-02-26 0.02 mg of ethinylostradiol (as betadexclathrate) and 3mg drospirenone

Country Status (11)

Country Link
CN (1) CN1223350C (en)
BG (2) BG109749A (en)
CA (1) CA2382426C (en)
EE (1) EE05317B1 (en)
HR (1) HRP20020258B1 (en)
IL (2) IL197396A (en)
MX (1) MXPA02002043A (en)
NO (3) NO327588B3 (en)
RU (4) RU2449796C9 (en)
SK (1) SK287634B6 (en)
UA (1) UA81387C2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
CN101489563A (en) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RU2618471C2 (en) * 2012-12-03 2017-05-03 Закрытое Акционерное Общество "Вертекс" Oral pharmaceutical composition of diuretics and ace inhibitor in micronized form, drug and its application
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN108606963B (en) * 2017-12-27 2021-05-18 上海长海医院 Compound contraceptive patch containing drospirenone and estrogen, preparation method and application
CN111529482A (en) * 2020-05-20 2020-08-14 祝培 Testosterone undecanoate sustained-release implant and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (en) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-methylene-spirolactones, processes for their preparation and pharmaceuticals containing them
DE4344462C2 (en) * 1993-12-22 1996-02-01 Schering Ag Composition for contraception
DE4411585A1 (en) * 1994-03-30 1995-10-05 Schering Ag Combined pharmaceutical preparation for hormonal contraception
ES2223081T3 (en) * 1996-07-26 2005-02-16 Wyeth MONOFASTIC ORAL ANTICONCEPTIVE METHOD AND KIT THAT INCLUDES A COMBINATION OF PROGESTINE AND STROGEN.

Also Published As

Publication number Publication date
IL197396A (en) 2010-04-29
RU2005131868A (en) 2007-04-20
RU2010114825A (en) 2011-10-20
MXPA02002043A (en) 2003-08-20
NO20083854L (en) 2002-04-26
BG109749A (en) 2008-06-30
CA2382426C (en) 2006-02-28
BG106533A (en) 2002-10-31
CA2382426A1 (en) 2001-03-08
NO20091809L (en) 2002-04-26
CN1223350C (en) 2005-10-19
RU2482853C2 (en) 2013-05-27
SK287634B6 (en) 2011-04-05
HRP20020258B1 (en) 2007-05-31
CN1407895A (en) 2003-04-02
RU2269342C2 (en) 2006-02-10
EE05317B1 (en) 2010-08-16
NO2010004I1 (en) 2010-03-22
RU2269342C9 (en) 2007-10-27
UA81387C2 (en) 2008-01-10
RU2449796C9 (en) 2007-10-27
SK2572002A3 (en) 2002-11-06
NO327588B3 (en) 2011-05-16
RU2396082C2 (en) 2010-08-10
BG65204B1 (en) 2007-07-31
HRP20020258A2 (en) 2005-02-28
IL200482A0 (en) 2011-07-31
RU2449796C2 (en) 2006-02-10
EE200900049A (en) 2009-10-15

Similar Documents

Publication Publication Date Title
NO20020801L (en) Pharmaceutical material of ethinylestradiol and drospirenone for use as a contraceptive
NO327588B1 (en) Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive
BG66095B1 (en) Pregelatinized starch in a controlled release preparation
KR970706004A (en) Hormonal Drugs and Their Use for the Treatment of Estrogen Deficiency (NOVEL HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES)
HRP20080394T3 (en) Peroral solid dosage form for contraception comprising dienogest and ethinylestradiol
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
NO20072687L (en) Pharmaceutical contraceptive preparation
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive
ECSP003721A (en) A PHARMACEUTICAL COMPOSITION TO BE USED AS AN CONTRACEPTIVE
EP2305267A3 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
TH54054B (en) Pharmaceutical mixtures for use as birth control pills
HRP20020666B1 (en) Drospirenone for hormone replacement therapy
UY29378A1 (en) PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION
TH148141A (en) Combination of estradiolvalerate or estradiol with dienogest for oral therapy in malfunctioning uterine bleeding In combination with oral contraceptives
TH80557B (en) Pharmaceutical products for oral contraception

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: YAZ 0,02 MG/3 MG TABLETTER, FILMDRASJERTE; NAT. REG. NO/DATE: 07-5386 20090422; FIRST REG. NO/DATE: NL , RGV33842 20070629

Spc suppl protection certif: 2010004

Filing date: 20100226

LC4 Limitation of patent rights - b3 (par. 39b patent act)

Effective date: 20110516

CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

REER Request for administrative reevaluation of patent

Opponent name: GEDEON RICHTER PLC, HU

BDEC Board of appeal decision

Free format text: KLAGESAKEN HEVES

Filing date: 20150320

Effective date: 20190628

MK1K Patent expired